Brief: HBM Holdings Says U.S. FDA Granted IND Clearance For B7H4X4-1BB Bispecific Antibody HBM7008
27/06/2022 11:29
June 27 (Reuters) - Hbm Holdings Ltd 2142.HK :
* GRANTED CLEARANCE OF IND FROM FDA OF U.S. FOR B7H4X4-1BB
BISPECIFIC ANTIBODY HBM7008
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study